Remon Medical also develops the Remon HeartLook, a device for
measurement of pulmonary artery pressure the most important
hemodynamic indicator in heart failure. A one-time, minimally
invasive catheter-based procedure will provide unlimited,
non-invasive home-based monitoring of the CHF patient's hemodynamic
status.
Israeli company Remon Medical Technologies, Inc., a privately owned
medical systems company, has announced that it has completed raising
a total of $26 million. Remon Medical's technology is integrated into
minute implants, requiring no antenna, wires, or connecting leads --
allowing a tiny device leads implanted deep inside the body to
communicate by means of radio waves with other implanted devices and
external systems. The company's intra-body communication, a novel
proprietary technology enables communication between its implantable
sensing or actuating platforms and other active implantable devices
in a totally wireless fashion. Remon Medical continues its clinical
trial of the Remon Impressure, a device that offers on-demand,
non-invasive means to monitor intra-aneurysm pressures following
endo-vascular graft procedures. The device was implanted and is being
used successfully in 21 patients in the Mount Sinai Hospital (New
York).